Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies

Mei-Hsuan Lee1,2*, Sheng-Nan Lu3*, Yong Yuan7, Hwai-I Yang2,4,5, Chin-Lan Jen2, San-Lin You2, Li-Yu Wang6, Gilbert L’Italien7,8, Chien-Jen Chen2,9* and for the R.E.V.E.A.L.-HCV Study Group

Introduction

Hepatitis C virus (HCV) affects approximately 130–210 million people worldwide, and it is one of the leading causes of chronic hepatitis, cirrhosis, and liver cancer [1,2]. Among patients chronically infected with HCV for 20–30 years, cirrhosis occurs in 20–30% [3]. Hepatocellular carcinoma develops in 1–4% of cirrhotic patients per year [4]. As a result of the successful hepatitis B virus vaccination program, HCV-related health burdens are emerging quickly in Asian countries [5].

Current US and European guidelines recommend screening for a history of risk of exposures to HCV and testing high-risk individuals who have identifiable risk factors [6,7,8]. However, fewer than half of those infected with HCV are aware of their infection [9,10] and they may play as the infection sources in the community. Recent decision analysis showed that broader screening for HCV would be cost effective [11] and to expand HCV screening to general population over the current practice of only screening high-risk individuals is advocated [12]. Thus, it should be important to develop risk assessment tool for the individuals who have been identified to be seropositive of HCV after the implementation of new strategies of screening.

Several algorithms based on serum biomarkers have been developed recently that have included combinations of serum
biomarkers to assist in the diagnosis of advanced liver disease [13,14,15,16,17,18]. However, these algorithms have not yet been validated for their ability to predict the risk of end-stage liver diseases before onset. In addition, these algorithms have not focused on hepatocellular carcinoma.

A simple-to-use risk prediction models for liver disease progression are useful for improving patient care and disease stratification. In this study, we developed a noninvasive risk score system for hepatocellular carcinoma by integrating routinely measured clinical parameters among hepatitis C patients who were part of the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HCV (R.E.V.E.A.L.-HCV) cohort. In addition, we applied the risk score system to an external cohort consisting of participants residing in an HCV-endemic area to validate its predictability.

Materials and Methods

Study population

R.E.V.E.A.L.-HCV Cohort for Risk Prediction Model Derivation. The R.E.V.E.A.L.-HCV cohort is derived from a community-based study which has been described previously [19,20,21]. In brief, participants living in seven townships in Taiwan provided written informed consent for interview, health examination, and blood collection during 1991–1992. Blood samples were obtained from each participant at study entry. In total, there were 1095 adults aged between 30–65 years old seropositive for antibodies against HCV (anti-HCV) but seronegative for hepatitis B surface antigen (HBsAg). They were followed till the end of 2008 for the incidence of hepatocellular carcinoma. The study protocol was approved by the institutional review board of the College of Public Health, National Taiwan University in Taipei.

High Risk Cohort for Risk Prediction Model Validation. Another cohort enrolled for the model validation included residents in southern Taiwan. The townships where the participants resided were endemic areas of HCV infection with high hepatocellular carcinoma mortality rates. The participants were invited to attend a community-based screening program in 2004–2005, and each participant provided informed written consent. The detailed enrollment procedures and characteristics of participants have been described previously [22,23,24]. In total, we selected 572 anti-HCV seropositives who were seronegative for HBsAg and aged between 30–65 years old in the validation cohort; the participants in this validation cohort were followed till the end of 2008.

Laboratory Examinations

The samples collected at study entry in both cohorts were tested for the seromarkers as followed. Tests on HBsAg, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level and anti-HCV were performed using commercial kits followed by standard procedures. The baseline serum samples collected from the participants in model derivation and validation cohorts were stored at −70°C until they were assayed for serum HCV RNA levels and HCV genotype. The serum HCV RNA was examined by the COBAS TaqMan HCV test, v2.0 (Roche Diagnostics, Indianapolis, NJ, USA). Serum samples with detectable HCV RNA were examined for HCV genotypes by LightCycler based PCR and melting curve analysis [20,25], in R.E.V.E.A.L.-HCV cohort or by direct sequencing in the validation cohort.

Ascertainment of Newly Developed Hepatocellular Carcinoma

Newly-developed hepatocellular carcinoma cases were identified by follow-up health examination and computerized data linkage. The participants in both cohorts obtained ultrasonography examinations performed by board-certified gastroenterologists every 6–12 months during follow-up. Once hepatocellular carcinoma was suspected sonographically, the patients were referred for confirmation based on the criteria of 1) histopathology; 2) two imaging techniques (abdominal ultrasonography, angiogram, or computed tomography); or 3) one imaging technique plus a serum α-fetoprotein level of 400 ng/mL or greater [26]. In addition to active follow-up, we performed computerized data linkage with the National Cancer Registration and the National Death Certification profiles from January 1, 1991, through December 31, 2008 to identify the occurrence of hepatocellular carcinoma.

Statistical Analysis

Descriptive statistics characterizing participants in model derivation and validation cohorts were estimated. Differences between the two cohorts were evaluated with independent t tests for continuous and chi-squared tests for categorical variables. The follow-up years of each participant was calculated from the baseline recruitment to the date of hepatocellular carcinoma diagnosis, the date of death, or the date of last follow-up, which came first.

Multivariable Cox regressions were used to estimate the hazard ratio for each parameter included in the prediction equation for hepatocellular carcinoma. The proportional hazards assumption was verified. Parameters with statistically significant (p<0.05) hazard ratios were included in the risk prediction model. The Cox’s proportional hazard regression coefficients of each included parameter were converted into an integer risk score by rounding the quotient of dividing the regression coefficient by a single constant. The constant selected was the regression coefficient for 5-year increase in age, allowing the integer risk score for a 5-year increase in age to be one [27]. The predicted risks for hepatocellular carcinoma were estimated by the sum of risk scores by the equation: $1 - P_0^{\exp \left( \sum \beta_i \times \text{score} - \Sigma M_i \right)}$, where $P_0$ was the baseline disease free probability, $\beta_i$ was the regression coefficient for the ith variables ($X_i$), and the $M_i$ denoted the mean level of $X_i$ [27].

To evaluate the predictive accuracy, the receiver operating characteristic (ROC) curve for each model was derived and the area under the ROC curve (AUROCs) was calculated. To evaluate the discriminatory ability of the risk models, the participants in both cohorts were classified into three groups by their sum risk scores, low, medium, high and the cumulative hepatocellular carcinoma risk of these three groups was estimated. The 25th and 75th percentiles of sum risk scores of patients affected with newly-developed hepatocellular carcinoma were used as the cutoff values in order to ensure that each group had an adequate number of hepatocellular carcinoma cases. The cumulative risk of hepatocellular carcinoma of participants with low, medium or high sum risk scores was estimated by Kaplan-Meier method, and the differences in cumulative hepatocellular carcinoma risk were compared by the log-rank test. All of the statistical analyses were performed by SAS version 9.1 (SAS Institute, Cary, NC).

PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e94760
Results

The baseline characteristics of participants in the model derivation and validation cohorts were compared in Table 1. There were significant differences in the baseline characteristics of the two cohorts. The validation cohort had a significantly higher proportion of participants with older age, elevated serum ALT (≥45 U/L) levels, detectable serum HCV RNA level, and cirrhosis status at study entry. The R.E.V.E.A.L.-HCV cohort was followed longer than the validation cohort with a median follow-up of 16.7 years, compared with 4.3 years for the validation cohort. Among the 975 participants in the R.E.V.E.A.L.-HCV cohort, 91 cases of hepatocellular carcinoma occurred after 14,821 person-years of follow-up, giving an incidence of 614 per 100,000 person-years. On the other hand, there were 52 incident hepatocellular carcinoma cases among 572 participants in the validation cohort after 2,265 person-years of follow-up, and the estimated incidence of hepatocellular carcinoma was 2296 per 100,000 person-years. Figure 1 showed the cumulative risk of hepatocellular carcinoma for participants in R.E.V.E.A.L.-HCV cohort and validation cohort, the latter had a significantly higher risk than the former (p<0.001). The higher hepatocellular carcinoma risk in the validation cohort reflected its more severe profile of risk predictors at study enrolment than the derivation cohort.

Derivation of Risk Prediction Model for Hepatocellular Carcinoma

We developed two risk prediction models. One was for all anti-HCV seropositives (included HCV RNA seropositives and HCV RNA seronegatives); and the other one was confining to the anti-HCV seropositives with detectable HCV RNA. All risk predictors included in each risk prediction model were statistically significantly associated with hepatocellular carcinoma (p<0.05) in the Cox’s proportional hazards regression analyses. The regression coefficients of predictors in the risk prediction models were converted into integer risk scores as shown in Table 2 and Table 3.

Table 1. Baseline characteristics of study participants and the number of hepatocellular carcinoma cases in model derivation and validation cohorts.

| Baseline Predictors | R.E.V.E.A.L.-HCV cohort | High risk validation cohort | P value† |
|---------------------|------------------------|-----------------------------|---------|
|                     | Total (N = 975), n (%) | HCC cases (n = 91)          |         |
| Age                 | 50.9 ± 9.3             | 55.1 ± 6.6                  |         |
| Mean ± SD           | 30–39                  | 163 (16.7)                  | 3       |
|                     | 40–49                  | 217 (22.3)                  | 11      |
|                     | 50–59                  | 399 (40.9)                  | 49      |
|                     | 60–65                  | 196 (20.1)                  | 28      |
| Sex                 | 550 (56.4)             | 45 (4.6)                    | 31      |
|                     | 425 (43.6)             | 386 (39.7)                  | 21      |
| Serum ALT Levels (U/L) | ≤15                    | 429 (44.0)                  | 19      |
|                     | 16–45                  | 387 (39.7)                  | 40      |
|                     | >45                    | 159 (16.3)                  | 32      |
| AST/ALT ratio       | <1                     | 340 (34.9)                  | 32      |
|                     | ≥1                     | 635 (65.1)                  | 59      |
| Liver cirrhosis     | No                     | 961 (98.6)                  | 85      |
|                     | Yes                    | 14 (1.4)                    | 6       |
| Serum HCV RNA levels* | HCV RNA undetectable   | 298 (30.6)                  | 5       |
|                     | Low RNA levels         | 339 (34.8)                  | 36      |
|                     | High RNA levels        | 338 (34.7)                  | 50      |
| HCV genotype†       | Genotype non-1         | 271 (29.5)                  | 20      |
|                     | Genotype 1             | 351 (38.2)                  | 50      |

Abbreviations: SD, standard deviation; AST, aspirate aminotransferase; ALT, alanine aminotransferase.
*2.3×10^4 as the cut-off for low and high serum levels of HCV RNA.
†HCV genotype was available only for those with detectable serum HCV RNA levels.
†‡compared the differences in the baseline characteristics for the participants in R.E.V.E.A.L.-HCV cohort and validation cohort.

doi:10.1371/journal.pone.0094760.t001

PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e94760

Prediction Model for HCV-HCC
The model among all anti-HCV seropositives (Table 2). On the other hand, the risk prediction model for anti-HCV seropositives with detectable HCV RNA had the sum risk scores ranged 0–18 (Table 3). The 5-year, 10-year, and 15-year predicted hepatocellular carcinoma risk by sum risk scores for the two models are shown in Table 4 and Table 5. Participants with higher sum risk scores had greater predicted risks of hepatocellular carcinoma. The 5-year

Figure 1. Cumulative risk of hepatocellular carcinoma after follow-up in (A) R.E.V.E.A.L.-HCV cohort and (B) high risk validation cohort in southern Taiwan.

doi:10.1371/journal.pone.0094760.g001
predicted hepatocellular carcinoma risk ranged 0.02–26.02%; the 10-year risk ranged 0.08–63.85%; and the 15-year risk ranged 0.19–91.04% for the prediction model among all anti-HCV seropositives (N = 975). Secondly, the predicted risk for 5-, 10-, and 15-year for anti-HCV seropositives with detectable RNA was 0.10–22.38%; 0.34–59.31%; and 0.81–88.32% in correspondingly.

Table 2. Coefficients and risk points of each baseline predictor for all anti-HCV seropositives (N = 975).

| Predictors                                         | Beta coefficient | Point | P value |
|----------------------------------------------------|------------------|-------|---------|
| Age at recruitment, 5 years increment              | 0.33             | 1     | <0.001  |
| Serum ALT Levels (U/L)                             |                  |       |         |
| ≤15                                                | Reference        | 0     |         |
| 16–45                                              | 0.47             | 1     | 0.12    |
| >45                                                | 1.23             | 4     | <0.001  |
| AAR                                                |                  |       |         |
| <1                                                 | Reference        | 0     |         |
| ≥1                                                 | 0.56             | 2     | 0.04    |
| Liver cirrhosis/HCV RNA level/HCV Genotype         |                  |       |         |
| Without LC/HCV RNA undetectable                    | Reference        | 0     |         |
| Without LC/Low RNA level/genotype non 1            | 1.41             | 4     | 0.01    |
| Without LC/High RNA level/genotype non 1           | 1.31             | 4     | 0.02    |
| Without LC/Low RNA level/genotype 1                | 1.73             | 5     | <0.001  |
| Without LC/High RNA level/genotype 1               | 2.05             | 6     | <0.001  |
| Liver cirrhosis                                    | 3.29             | 10    | <0.001  |

Table 3. 5-, 10-, and 15-year predicted risk and 95% confidence interval for hepatocellular carcinoma among all anti-HCV seropositives (N = 975).

| Sum of risk score | 5-year predicted risk (95% CI), % | 10-year predicted risk (95% CI), % | 15-year predicted risk (95% CI), % |
|-------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| 0                 | 0.02 (0.01–0.04)                  | 0.08 (0.04–0.12)                  | 0.19 (0.11–0.26)                  |
| 1                 | 0.03 (0.01–0.06)                  | 0.11 (0.06–0.16)                  | 0.26 (0.16–0.36)                  |
| 2                 | 0.04 (0.01–0.08)                  | 0.15 (0.08–0.22)                  | 0.36 (0.22–0.49)                  |
| 3                 | 0.06 (0.02–0.11)                  | 0.21 (0.11–0.31)                  | 0.49 (0.30–0.68)                  |
| 4                 | 0.09 (0.02–0.15)                  | 0.29 (0.15–0.43)                  | 0.68 (0.42–0.94)                  |
| 5                 | 0.12 (0.03–0.20)                  | 0.40 (0.21–0.59)                  | 0.94 (0.58–1.31)                  |
| 6                 | 0.16 (0.05–0.28)                  | 0.55 (0.29–0.81)                  | 1.30 (0.80–1.80)                  |
| 7                 | 0.23 (0.06–0.39)                  | 0.76 (0.40–1.13)                  | 1.80 (1.11–2.49)                  |
| 8                 | 0.31 (0.09–0.54)                  | 1.06 (0.55–1.56)                  | 2.49 (1.53–3.43)                  |
| 9                 | 0.44 (0.12–0.75)                  | 1.46 (0.77–2.15)                  | 3.43 (2.12–4.72)                  |
| 10                | 0.60 (0.17–1.04)                  | 2.02 (1.06–2.97)                  | 4.72 (2.92–6.48)                  |
| 11                | 0.83 (0.23–1.43)                  | 2.78 (1.47–4.09)                  | 6.48 (4.03–8.87)                  |
| 12                | 1.15 (0.32–1.98)                  | 3.84 (2.03–5.61)                  | 8.86 (5.53–12.07)                 |
| 13                | 1.59 (0.44–2.73)                  | 5.27 (2.80–7.69)                  | 12.06 (7.58–16.32)                |
| 14                | 2.20 (0.61–3.76)                  | 7.23 (3.85–10.49)                 | 16.31 (10.34–21.87)               |
| 15                | 3.03 (0.85–5.17)                  | 9.88 (5.29–14.23)                 | 21.85 (14.04–28.96)               |
| 16                | 4.18 (1.18–7.09)                  | 13.41 (7.26–19.16)                | 28.93 (18.90–37.72)               |
| 17                | 5.74 (1.62–9.68)                  | 18.09 (9.91–25.52)                | 37.69 (25.19–48.11)               |
| 18                | 7.86 (2.24–13.16)                 | 24.15 (13.46–33.51)               | 48.07 (33.10–59.69)               |
| 19                | 10.72 (3.09–17.75)                | 31.81 (18.15–43.18)               | 59.66 (42.70–71.60)               |
| 20                | 14.54 (4.26–23.71)                | 41.15 (24.23–54.03)               | 71.56 (53.76–82.51)               |
| 21                | 19.55 (5.85–31.26)                | 52.03 (31.91–66.20)               | 82.48 (55.65–91.06)               |
| 22                | 26.02 (8.01–40.51)                | 63.85 (41.27–77.74)               | 91.04 (77.24–96.48)               |
Validation of Risk Prediction Models for Hepatocellular Carcinoma

In the evaluation of predictive accuracy of the risk model, the AUROCs for predicting 5-, 10- and 15-year hepatocellular carcinoma risk in the derivation set were 0.75, 0.83, 0.83 for model with all anti-HCV seropositives. On the other hand, the AUROC was 0.65, 0.77 and 0.73 for predicting the 5-, 10-, and 15-year risk of hepatocellular carcinoma. They indicated the sum risk scores had satisfactory to high validity for the prediction of hepatocellular carcinoma risk. The AUROCs for predicting 5-year hepatocellular carcinoma risk in the validation set was 0.73 and 0.70 for the two models.

In the evaluation of discriminatory ability of risk model in the validation set, participants with newly-developed hepatocellular carcinoma were found to have significantly higher sum risk scores than those unaffected (p < 0.001) in each model. By applying to the model among all anti-HCV seropositives, the 25th and 75th percentile of the sum risk score among the anti-HCV seropositives affected with hepatocellular carcinoma in the validation set were 13 and 19. By using these values as cut-offs, the participants in the

| Table 4. Coefficients and risk points of each baseline predictor for anti-HCV seropositives with detectable HCV RNA (N = 677). |
| Predictors | Beta coefficient | Point | P value |
| Age at recruitment, 5 years increment | 0.31 | 1 | <0.001 |
| Serum ALT Levels (U/L) | 0.41 | 1 | 0.19 |
| >45 | 1.09 | 4 | 0.003 |
| Liver cirrhosis/HCV genotype/HCV RNA levels | | | |
| Without LC/genotype non 1 | Reference | 0 |
| Without LC/genotype 1/low RNA levels | 0.34 | 1 | 0.29 |
| Without LC/genotype 1/high RNA levels | 0.75 | 2 | 0.01 |
| Liver cirrhosis | 1.97 | 6 | <0.001 |

doi:10.1371/journal.pone.0094760.t004

| Table 5. 5-, 10-, and 15-year predicted risk and 95% confidence interval for hepatocellular carcinoma among anti-HCV seropositives with detectable HCV RNA (N = 677). |
| Sum of risk score | 5-year predicted risk (95% CI), % | 10-year predicted risk (95% CI), % | 15-year predicted risk (95% CI), % |
| 0 | 0.10 (0.03–0.14) | 0.34 (0.19–0.42) | 0.81 (0.55–0.91) |
| 1 | 0.13 (0.04–0.19) | 0.46 (0.27–0.57) | 1.11 (0.75–1.24) |
| 2 | 0.18 (0.05–0.26) | 0.63 (0.36–0.77) | 1.50 (1.03–1.69) |
| 3 | 0.24 (0.07–0.36) | 0.86 (0.49–1.05) | 2.04 (1.40–2.29) |
| 4 | 0.33 (0.09–0.49) | 1.17 (0.67–1.42) | 2.78 (1.90–3.11) |
| 5 | 0.45 (0.13–0.66) | 1.59 (0.91–1.94) | 3.76 (2.58–4.22) |
| 6 | 0.61 (0.17–0.90) | 2.17 (1.24–2.63) | 5.09 (3.50–5.71) |
| 7 | 0.84 (0.23–1.23) | 2.94 (1.69–3.57) | 6.88 (4.73–7.69) |
| 8 | 1.14 (0.32–1.67) | 3.99 (2.29–4.83) | 9.26 (6.40–10.34) |
| 9 | 1.55 (0.43–2.28) | 5.39 (3.11–6.52) | 12.40 (8.61–13.82) |
| 10 | 2.11 (0.59–3.07) | 7.28 (4.22–8.79) | 16.51 (11.55–18.35) |
| 11 | 2.86 (0.80–4.17) | 9.78 (5.70–11.78) | 21.50 (15.41–24.14) |
| 12 | 3.88 (1.09–5.63) | 13.09 (7.69–15.70) | 28.47 (20.39–31.37) |
| 13 | 5.25 (1.48–7.60) | 17.41 (10.34–20.77) | 36.66 (26.71–40.14) |
| 14 | 7.08 (2.02–10.21) | 22.94 (13.82–27.19) | 46.34 (34.53–50.31) |
| 15 | 9.52 (2.74–13.65) | 29.90 (18.34–35.10) | 57.19 (43.86–61.45) |
| 16 | 12.75 (3.71–18.13) | 38.38 (24.13–44.53) | 68.53 (54.47–72.72) |
| 17 | 16.96 (5.02–23.87) | 48.31 (31.37–55.21) | 79.31 (65.78–82.97) |
| 18 | 22.38 (6.78–31.04) | 59.31 (40.13–66.53) | 88.32 (76.81–91.04) |

doi:10.1371/journal.pone.0094760.t005
The observed cumulative hepatocellular carcinoma risks of three groups are compared in Figure 2A. Secondly, by applying to the model confining to the RNA seropositives, the 25th and 75th percentile of the sum risk score among the anti-HCV seropositives with detectable HCV RNA was 15 and 19. By using the two cut-offs, the participants with detectable HCV RNA in the validation set could be differentiated into three groups and the cumulative risk of hepatocellular carcinoma of the three groups were depicted in

![Cumulative Risk of Hepatocellular Carcinoma](image)

**Figure 2. Cumulative risk of hepatocellular carcinoma of participants stratified by their sum of risk score in high risk validation cohort.** (A) all anti-HCV seropositives (risk score <13 for low-risk, 13–18 for medium-risk, and ≥19 for high-risk group) (B) anti-HCV seropositives with detectable HCV RNA (risk score <9 for low-risk, 9–15 for medium-risk, and ≥15 for high-risk group).

doi:10.1371/journal.pone.0094760.g002
divided into three distinctive groups with low-, medium-, score system, the participants in the validation cohort could be cohort, the prediction accuracy was satisfactory. By using the risk prediction models developed from a derivation cohort. The niche of our study was that the prediction models could be widely utilized for consultations. Secondly, our risk prediction models did not include liver histology because the liver biopsy is not practical in these community-based studies. However, we included the AST to ALT ratio as a proxy of liver fibrosis status.

To our best knowledge, this study was the first one to develop and validate hepatocellular carcinoma risk models among asymptomatic hepatitis C carriers. The major limitation of this study was the validation cohort had a shorter follow-up period than that of the model derivation cohort. Thus, only the 5-year predicted risk for hepatocellular carcinoma could be validated. However, in our previous study we found that the serum levels of HCV RNA and ALT and HCV genotype were long-term predictors for hepatocellular carcinoma.[20] It was expected that the AUROC of the 10- and 15-year predicted risk for hepatocellular carcinoma should be improved in the validation cohort. The niche of our study was that the prediction models could be applied to relatively healthy patients with hepatitis C at early clinical stages. The predicted end-stage liver diseases could thus be prevented earlier. Individuals with high risk for hepatocellular carcinoma should be consulted for appropriate therapeutic management and intensively monitored to detect hepatocellular carcinoma at early stage.
Our scoring system models were developed from a long-term follow-up cohort with a moderate size. In addition, the models were validated in another sizable cohort and confirmed to have a satisfactory accuracy and discriminatory ability. Moreover, the parameters included are commonly recorded in clinics, which indicate that the scoring system could be used routinely in the clinic. The clinical practice guidelines indicate that all treatment-naive patients with compensated disease and patients with fibrosis should be considered for therapy [36]. However, in patients with less severe disease, the indication for therapy should be individualized [36]. Our study enrolled asymptomatic chronic hepatitis C and estimated their risk profiles to provide useful information for the triage and clinical management of patients.

In conclusion, our risk prediction models combine readily available parameters in clinical practice and could be used to help physicians develop a disease management strategy. The prediction models had satisfactory discriminatory ability to differentiate patients into low, medium, and high risk for hepatocellular carcinoma and would be useful for planning therapeutic strategies and optimal utilization of health care resources.

Disclaimers
All authors of this research paper have directly participated in the planning, execution, or analysis of the study. All authors of this paper have read and approved the final version submitted.

The contents of this manuscript have not been copyrighted or published previously. The contents of this manuscript are not now under consideration for publication elsewhere.

The contents of this manuscript will not be copyrighted, submitted, or published elsewhere while acceptance by the Journal is under consideration.

There are no directly related manuscripts or abstracts, published or unpublished, by any author of this paper.

Author Contributions
Conceived and designed the experiments: MHL, HIY, CJC. Performed the experiments: MHL, YY, SNL, HIY, CLJ, SLY, GLJ, CJC. Analyzed the data: MHL. Contributed reagents/materials/analysis tools: MHL, YY, SNL, HIY, CLJ, SLY, GLJ, CJC. Wrote the paper: MHL. Critically revised the manuscript for important intellectual content: MHL, YY, SNL, HIY, CLJ, SLY, GLJ, CJC. Performed statistical analysis: MHL. Obtained funding: CJC. Provided administrative, technical, or material support: MHL, YY, SNL, HIY, CLJ, SLY, GLJ, CJC.

References
1. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29 Suppl 1: 74–81.
2. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 550–567.
3. Hoofnagle JH, Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. New England Journal of Medicine 355: 2444–2451.
4. Fattovich G, Suroldi T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127: 853–850.
5. Lu SN, So WW, Yang NS, Chang TT, Chong KS, et al. (2006) Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. International Journal of Cancer 119: 1946–1952.
6. [No authors listed] (1999) EASL International Consensus Conference on Hepatitis C. Paris, 26–28 February, 1999. Consensus Statement. European Association for the Study of the Liver. J Hepatol 30: 956–961.
7. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigby MO, et al. (2004) Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Annals of Internal Medicine 141: 715–717.
8. Hatzakis A, Waid S, Bruix J, Buti M, Carballo et al. (2011) The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 18 Suppl 1: 1–16.
9. Denniston MM, Kleevens RM, McQuillan GM, Jiles RB (2012) Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology 55: 1652–1661.
10. Varela M, Reig M, de la Mata M, Manilla A, Bastianante J, et al. (2010) [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc) 134: 569–576.
11. Coffin PO, Scott JD, Golden MR, Sullivan SD (2012) Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C. Clinical Infectious Diseases 54: 1259–1271.
12. Deuffic-Burban S, Yazdanpanah Y (2012) It Is Time to Change the Paradigm for Hepatitis C Virus Testing. Clinical Infectious Diseases 54: 1272–1274.
13. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, et al. (2010) A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 141: 141–149.
14. Ghaney MG, Lok AS, Everhart JE, Everson GT, Lee WM, et al. (2010) Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 138: 136–146.
15. Imbert-Bismut F, Ratinov L, Percon E, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069–1075.
16. Lok AS, Seeff LB, Morgan TR, di Biase MG, Sterling RK, et al. (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136: 138–148.
17. Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, et al. (2006) A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 44: 1086–1097.
18. Fontana RJ, Dienstag JL, Bokovský HL, Sterling RK, Naidadhun D, et al. (2010) Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 59: 1401–1409.
19. Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, et al. (2011) Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991–2. Gut 60: 680–694.
20. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, et al. (2010) Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 28: 4587–4593.
21. Lee MH, Yang HI, Lu SN, Jen CL, You SL, et al. (2012) Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. J Infect Dis 206: 469–477.
22. Huang YC, Huang CF, Chang KC, Hung SF, Wang JH, et al. (2011) Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area. J Gastroenterol Hepatol 26: 129–134.
23. Lu SN, Wang JH, Chen PF, Tseng HD, Tseng PL, et al. (2008) Community-based mass ultrasonographic screening of hepatocellular carcinoma among thronboscytopenic adults. Cancer Epidemiol Biomarkers Prev 17: 1813–1821.
24. Tseng PL, Wang JH, Tsung HD, Hung CH, Koo KM, et al. (2010) Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol 25: 1426–1434.
25. Yeh SH, Tsai CY, Kuo JH, Liu CJ, Kuo TJ, et al. (2004) Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. Journal of Hepatology 41: 659–666.
26. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421–430.
27. Sullivan LM, Massaro JM, D’Agostino RB Sr. (2004) Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 23: 1631–1660.
28. Volk ML, Tocco R, Saini S, Lok AS (2009) Public health impact of antiviral therapies for hepatitis C in the United States. Hepatology 50: 1750–1753.
29. Tsai MC, Kee KM, Chen YD, Lin LG, Tsai LS, et al. (2007) Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 22: 92–98.
30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B polymorphism in chronic hepatitis C is associated with response to pegylated interferon and ribavirin therapy. Nature Genetics 41: 1100–U1181.
32. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.

33. Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, et al. (2012) Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 93: 644–649.

34. Liu CH, Kao JH (2011) Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. J Gastroenterol Hepatol 26: 1348–1353.

35. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, et al. (2011) Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53: 7–13.

36. (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245–264.